| 5/17/2023 |
Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201 |
| 5/10/2023 |
Lumen Bioscience Awarded $8.1 million from U.S. Department of Defense to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses |
| 1/5/2023 |
Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress |
| 1/4/2023 |
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea |
| 12/23/2022 |
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections |
| 12/20/2022 |
BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study |
